Outcomes of Breast and Ovarian cancer patients with HRD/BRCA gene alterations treated with PARP inhibitors at a tertiary care hospital in Eastern India. - BROCA-PI

开始日期2023-11-13

申办/合作机构

Institute of Medical Sciences & SUM Hospital

100 项与 3-Aminobenzamide 相关的临床结果

登录后查看更多信息

100 项与 3-Aminobenzamide 相关的转化医学

登录后查看更多信息

100 项与 3-Aminobenzamide 相关的专利（医药）

登录后查看更多信息

5,212

项与 3-Aminobenzamide 相关的文献（医药）

2025-12-01·Current Urology Reports

Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer

Review

作者: Mossanen, Matthew ; Carvalho, Filipe L F ; D'Andrea, Vincent D ; Magnani, Christopher J. ; Clinton, Timothy N. ; Clinton, Timothy N ; Ernandez, John ; D’Andrea, Vincent D. ; Mouw, Kent W ; Bellmunt, Joaquim ; Magnani, Christopher J ; Carvalho, Filipe L. F. ; Mouw, Kent W.

PURPOSE OF REVIEW:

This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which integrate DDR inhibitors with standard chemotherapy and immunotherapy.

RECENT FINDINGS:

Noteworthy findings include the ATLANTIS trial, which demonstrated prolonged progression-free survival (PFS) in DDR biomarker-selected patients using PARP inhibitors as maintenance after standard chemotherapy. Trials such as BAYOU, which combined immunotherapy with PARP inhibition, similarly suggested a potential therapeutic benefit in DDR biomarker-selected patients with bladder cancer. Efforts to develop bladder-sparing treatment regimens based on DDR-associated mutational profiles, such as the RETAIN and HCRN 16-257 trials, have had mixed outcomes to date. There are now ongoing efforts to combine DDR inhibitors with the newest bladder cancer therapies, such as antibody-drug conjugates. This review highlights the most recent advances in targeting DNA repair deficiency in the evolving treatment landscape of bladder cancer.

2025-12-01·Journal of Gastrointestinal Cancer

Advances in Novel Targeted Therapies for Pancreatic Adenocarcinoma

Review

作者: Tsang, Erica S ; Hoang, Tuan

PURPOSE:

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with limited therapeutic options and poor prognosis. Recent advances in targeted therapies have opened new avenues for intervention in PDAC, focusing on key genetic and molecular pathways that drive tumor progression.

METHODS:

In this review, we provide an overview on advances in novel targeted therapies in pancreatic adenocarcinoma.

RESULTS:

Here, we explore the latest development in targeting the KRAS pathway, a historically "undruggable" target crucial to PDAC pathogenesis. Strategies to inhibit KRAS include direct KRAS-targeted therapies, modulation of upstream and downstream signaling, KRAS-specific siRNA, and novel combination therapies integrating KRAS inhibitors with immune checkpoint blockade, PARP inhibitors, chemotherapy, CDK4/6 inhibitors, and autophagy modulators. Beyond KRAS, emerging targets such as NRG1 fusions, NTRK/ROS1 fusions, RET alterations, and the PRMT5/CDKN2A/MAT2A axis, along with EGFR and Claudin18.2 inhibitors, are also discussed as promising therapeutic strategies. Additionally, the review highlights novel approaches for microsatellite instability-high (MSIH) PDAC and emerging therapies, including adoptive cell therapies (CAR-T, TCR, TIL), cancer vaccines, and strategies to modify the tumor microenvironment.

CONCLUSION:

Overall, the rapid evolution of targeted therapies offers renewed optimism in the fight against pancreatic cancer, a malignancy with historically poor outcomes.

2025-12-01·MOLECULAR BIOLOGY REPORTS

Clinical aspect of male breast cancer: a burgeoning and unaddressed issue

Review

作者: Mukherjee, Sukhes ; Ray, Suman Kumar

Rare among male cancers, male breast cancer (MBC) accounts for less than one percent of all male tumors. The prevalence of this illness and female breast cancer (FBC) have both been on the rise in recent years. While reports have implicated hormonal, environmental, and genetic variables in the development of MBC, nothing is known about its aetiology. Radiation exposure, hormonal imbalances caused by other medical conditions, and, most significantly, a positive family history of breast cancer-which indicates a hereditary predisposition-are major risk factors. While low-penetrance gene mutations (such as CHEK-2) are more prevalent, they do not enhance the risk of breast cancer development to the same extent as rare mutations in high-penetrance genes (such as BRCA1 and BRCA2). Speculated risk factors, including BRCA2 and lifestyle changes in the last few decades, are considered in light of the reasons for the rising occurrence. Topics covered include aromatase inhibitors, fulvestrant, and the prolactin and androgen receptor targeting pathways, as well as the therapeutic therapy of male breast cancer. Invasive ductal carcinomas, which account for about 90% of breast cancers in men, express many hormone receptors and show clear signs of treatment benefit. No single therapy method has been supported by published evidence from prospective randomized trials in MBC to yet. The treatment decision should be guided by the primary prognostic markers, which include tumor size and the number of axillary nodes involved. Detailed descriptions of the clinicopathologic characteristics of MBC are included in the present review. Our focus is on molecular profiling of MBC as a means to discover potential biomarkers and potential pharmacologic intervention targets. Endocrine treatment, which includes tamoxifen, aromatase inhibitors, and GnRH analogues, as well as cytotoxic chemotherapy, are characterized in light of the existing research. We also outline the possible function of targeted medications such as HER2-directed treatments, PARP inhibitors, and angiogenesis inhibitors.

123

项与 3-Aminobenzamide 相关的新闻（医药）

2025-06-05

·ioncology

王廷教授团队：从AACR三项研究结果看乳腺癌BRCA遗传检测的重要性

背景乳腺癌是全球女性发病率最高的恶性肿瘤[1]，其分子分型（如激素受体阳性、HER2阳性、三阴性乳腺癌）对治疗策略的选择至关重要。近年来，随着精准医学的发展，BRCA1/2基因突变检测逐渐成为乳腺癌个体化治疗的重要环节。BRCA1/2基因是关键的DNA修复基因，其突变不仅与遗传性乳腺癌的高风险相关，还可能影响化疗敏感性、手术决策及靶向治疗的选择[2]。然而，长期以来BRCA检测的临床应用主要关注于三阴性乳腺癌 (TNBC) 患者，尤其年龄小于60岁的TNBC患者。近年来随着PARP抑制剂在乳腺癌中的研究进展[3]， BRCA1/2的检测人群从TNBC患者群体逐渐扩展至HER2阴性人群 (IHC 0-2+，或IHC 2+且FISH-)。作为HER2阴性 (HER2-) 人群中的多数人群，激素受体阳性 (HR+) 乳腺癌患者是否需常规进行BRCA检测仍存在争议。2025年AACR会议上，来自中国空军军医大学第一附属医院（西京医院）甲乳腺血管外科王廷教授团队的三项真实世界单中心研究，首次系统探讨了这一问题，揭示了在HR+乳腺癌中检测BRCA突变独特的临床价值与必要性。我们对这三项研究的通讯作者王廷教授团队进行了专访，将其观点汇总，以飨读者。Q1HR+乳腺癌患者是否需要进行BRCA遗传检测？传统观点认为BRCA突变多见于TNBC，为何要关注HR+人群？专家观点传统认知中，BRCA突变确实与TNBC关联更紧密，但在临床实践过程中也观察到HR+这个群体BRCA突变率同样不低。加之国家药监局（NMPA）基于OlympiA[4]、FABULOUS[5]和OlympiAD[6]研究结果，批准了两个PARP抑制剂分别用于治疗携带胚系致病或疑似致病BRCA突变、HER2-早期和晚期乳腺癌患者。HR+乳腺癌是乳腺癌中最大的亚群，研究其胚系BRCA突变意义重大。在遗传评估方面，可为患者及家属提供关键信息，评估遗传风险；在治疗指导上，能为HR+乳腺癌患者提供精准治疗依据。从我们自己的一项真实世界研究结果中可窥端倪。数据支持1. 突变率不容忽视：针对1033例中国乳腺癌患者的研究显示，HR+患者中胚系BRCA1/2突变 (gBRCA1/2突变) 合并突变率为7.8% (gBRCA1突变, 2.6%，gBRCA2突变, 5.2%)[7]。Luminal B (HER2-) 患者gBRCA1/2突变率达到10.95%，虽然低于TNBC的19.8%[7]，但这一比例已足以影响临床决策。2. 亚型特异性分布：在HR+亚型中，Luminal B (HER2-) 患者的gBRCA2突变率高达6.8%，显著高于其他亚型 (P<0.001)，见下图[7] 。尤其值得注意的是，年龄≤40岁，T3/T4期，Luminal B (HER2-) 患者的gBRCA2突变率提升至26.9%[7]，提示年轻、肿瘤分期较高的HR+患者可能成为BRCA筛查的重点人群。3. 临床相关性：多因素回归分析发现，gBRCA2突变与肿瘤晚期 (T3/T4，P=0.034) 、高Ki-67指数 (P=0.015) 显著相关[7]。这意味着即使肿瘤为HR+，若存在BRCA2突变，其生物学行为可能更具侵袭性。△不同乳腺癌患者的gBRCA1或gBRCA2突变率[7]△gBRCA1或gBRCA2相关多因素分析[7]结论对于HR+患者，尤其是以下高危人群，BRCA检测具有明确必要性：年龄≤40岁的年轻患者；肿瘤分期较晚 (T3/T4) 或高Ki-67指数；Luminal B (HER2-) 亚型；其它遗传高危特征，如乳腺癌家族史或双侧乳腺癌病史等；Q2BRCA突变如何影响乳腺癌患者的治疗决策？从手术到系统治疗，检测结果如何指导临床？专家观点BRCA状态不仅影响遗传风险评估，更直接关联手术方式、化疗方案及靶向治疗选择。1. 手术决策：从保乳到预防性对侧乳房切除术 (CPM)：携带gBRCA1/2突变的患者选择CPM的比例显著高于非突变者 (8.6% vs. 1.7%, P＜0.001) [8]。2. 乳房重建偏好：年轻 (≤40岁) gBRCA2突变患者中，89.7%选择乳房切除术或乳房重建手术，而仅10.3%选择保乳手术；年轻 (≤40岁) gBRCA2阴性患者中这一比率分别为65.6%和34.4% (P=0.011)[8]。这表明，BRCA状态可能影响患者对降低复发风险与保留外观的权衡。△乳腺癌患者gBRCA状态与选择预防性对侧乳房切除之间的相关性[8]△早期、年轻乳腺癌患者gBRCA状态与选择保乳手术的相关性[8]3. 化疗敏感性：从病理完全缓解到潜在耐药，BRCA基因突变生物学异质性新辅助化疗 (NAC) 响应：gBRCA1突变患者接受标准的新辅助化疗病理完全缓解 (pCR) 率高达60.6%，残留肿瘤负荷（RCB） 0/Ⅰ比率更是达到69.7%；且无论是在HER2-，Luminal B (HER2-) 和TNBC各亚型中，gBRCA1突变与新辅助化疗获益密切相关[9]。gBRCA2的潜在耐药性：一个有趣的发现，gBRCA2突变可能与Luminal B (HER2-) 患者接受新辅助化疗耐药相关，携带gBRCA2突变Luminal B (HER2-)接受标准的新辅助化疗pCR只有6.7%，而携带gBRCA1突变却可达57.1%。进一步分析显示淋巴结阳性患者中，gBRCA2突变者的pCR率为0%[9]。这一发现也进一步提示BRCA1/2基因在预测新辅助化疗疗效方面存在显著的异质性。△乳腺癌患者gBRCA1/2突变状态和临床病理特征的相关性[9]4. 靶向治疗：PARP抑制剂的潜在应用OlympiA更新数据[10]（中位随访时间6.1年）显示，HER2-、gBRCA突变且具有高复发风险的早期乳腺癌患者，在完成新辅助治疗、辅助治疗及局部治疗后接受为期1年PARP抑制剂强化治疗显著延长了iDFS、DDFS和OS，且TNBC、HR+亚组获益一致。此外，约90%的患者在奥拉帕利治疗6年后仍存活，进一步强化早期HER2-乳腺癌中BRCA检测的重要性。此外，近期基于III期FABULOUS[5]研究，氟唑帕利在国内获批用于治疗携带gBRCA突变、HER2-晚期乳腺癌。在FABULOUS研究中，HR+患者占比超50%[5]。对于HR+晚期乳腺癌患者，早期识别关键基因突变（如BRCA突变）可指导一线和二线治疗方案选择，确保治疗的连续性和有效性。例如，一线使用CDK4/6抑制剂后，二线可精准选择PARP抑制剂等靶向药物。通过精准检测，医生能分析患者基因突变，制定个性化方案，更准确预测疗效和预后，提高患者获益。Q3中国乳腺癌患者的BRCA突变是否有独特特征？与西方人群相比有何差异？专家观点中国人群的BRCA突变谱呈现两大特点，可针对性调整筛查策略：1. 亚型分布差异gBRCA2在Luminal B (HER2-) 中的高占比：尽管目前多数研究显示BRCA2突变更多见于ER阳性患者[11]，但本研究数据显示[7]，在Luminal B (HER2-) 亚型的gBRCA2突变率高达6.8%，这显著高于既往基于西方人群所报道ER阳性人群~3%的BRCA2突变率[12,13]。这可能与人群遗传背景或环境因素有关；当然也可能和检测人群的选择偏倚所致，期待能更多数据能验证差异。年轻患者HR+群体BRCA突变比例较高：中国乳腺癌患者的中位发病年龄较西方早10-15年[1,14,15]。本研究显示，BRCA突变与年龄密切相关，无论BRCA1，还是BRCA2，在≤40岁群体中突变率较高，且在≤40岁的HR+患者中，gBRCA2突变尤为显著[7]，提示需加强年轻HR+乳腺癌人群的筛查。2. 临床病理特征的强相关性高T分期肿瘤的预警价值：T3/T4期、Luminal B (HER2-)、年轻患者 (≤40岁) gBRCA2突变率高达26.9%，远超其他亚型[7]，提示这类患者即使HR+，也可能需要更积极的系统治疗。Q4当前研究的局限性及未来方向？如何推动BRCA检测在HR+患者中的普及？专家观点现有研究为真实世界单中心回顾性分析，存在以下局限性：1. 样本量不足：如新辅助研究仅纳入452例患者，亚组分析（如HER2阳性）的统计效力较低。2. 缺乏生存终点数据：目前结论基于临床病理特征、手术方式、新辅助疗效数据分析，但长期生存数据，如无病生存期 (DFS) 和总生存期 (OS) 数据仍需追踪。未来研究方向：1. 多中心前瞻性队列：建立中国HR+乳腺癌患者的BRCA突变数据库，结合基因组学（如HRR通路其他基因）和转录组学分析，多维度探索HR+乳腺癌遗传突变特征谱，特别是BRCA1和BRCA2突变生物学特征差异，从而为HR+乳腺癌精准治疗提供依据。2. 探索新型治疗策略：PARP抑制剂在携带BRCA突变HR+患者中的疗效验证；BRCA突变与内分泌治疗耐药的关系（如ESR1突变协同效应）；3. 优化筛查策略：结合临床特征（如年龄、HER2状态，肿瘤分期）制定个性化HR+分层BRCA突变筛查策略；BRCA基因突变复杂，无热点突变，除了常见突变，还存在大片段缺失，应该优先选择NMPA获批的试剂盒开展检测，保证检测质量。结语BRCA遗传检测正在重塑乳腺癌的诊疗方式，对于HR+患者，尤其是年轻、特定分子亚型者，BRCA状态已成为不可忽视的预后和预测标志物。通过整合基因检测与临床特征，我们不仅能优化手术、化疗和靶向治疗策略，还能为患者直系亲属等高危人群提供健康管理方案。目前，国内已有NMPA批准的BRCA检测试剂获批应用于临床，在保证检测质量的同时也大幅提高BRCA遗传检测的可及性。未来，随着中国乳腺癌数据的积累及治疗手段的创新，BRCA检测将助力乳腺癌诊疗加快实现精准化、个性化。参考文献上下滑动查看更多内容[1] Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025. 31(4): 1154-1162.[2] Bedrosian I, Somerfield MR, Achatz MI, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol. 2024. 42(5): 584-604.[3] Morganti S, Marra A, De Angelis C, et al. PARP Inhibitors for Breast Cancer Treatment: A Review. JAMA Oncol. 2024. 10(5): 658-670.[4] Tutt A, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021. 384(25): 2394-2405.[5] Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m). ESMO Virtual Plenary. ,9.[6] Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019. 30(4): 558-566.[7] Comprehensive profiling of gBRCA1 and gBRCA2 variants in hormone receptorpositive breast cancer of Chinese patients. AACR. ,2025.[8] Impact of gBRCAs mutation on the surgery decisions of Chinese breast cancer patients: a single-center real-world study in Xijing Hospital, Northwest China. AACR. ,2025.[9] The predictive effect of gBRCAs mutations on rates of pathological complete response after neoadjuvant chemotherapy in Chinese breast cancer patients:a single-center study in Xijing Hospital, Northwest China. AACR. ,2025.[10] OlympiA: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w/ germline BRCA1 & BRCA2 pathogenic variants & highrisk HER2-negative primary breast cancer: longerterm follow. SABCS. ,2024.[11] Li PC, Zhu YF, Cao WM, Li B. ER-positive and BRCA2-mutated breast cancer: a literature review. Eur J Med Res. 2024. 29(1): 30.[12] Vocka M, Zimovjanova M, Bielcikova Z, et al. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. Cancers (Basel). 2019. 11(6): 738.[13] Tung N, Lin NU, Kidd J, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016. 34(13): 1460-8.[14] 令狐锐霞, 司文, 李莹, 杨俊兰. 3846例乳腺癌流行病学及临床病理学分析. 解放军医学院学报. 2015. (10): 1017-1021,1038.[15] Leong SP, Shen ZZ, Liu TJ, et al. Is breast cancer the same disease in Asian and Western countries. World J Surg. 2010. 34(10): 2308-24.王廷博士空军军医大学西京医院甲乳血管外科主任副教授、副主任医师、硕士导师美国M.D.Anderson癌症中心访问学者中华医学会肿瘤学分会乳腺肿瘤学组委员中国抗癌协会乳腺癌专业委员会（CBCS）委员中国抗癌协会乳腺癌整合防筛专业委员会常委中国医师协会外科医师分会乳腺外科医师委员会委员陕西省医师协会乳腺甲状腺医师分会副会长中华实验外科杂志中华乳腺病杂志编委樊菁西京医院甲乳血管外科副主任医师、副教授、医学博士中国医药教育协会乳腺疾病青年委员会副主任委员中国医药教育协会肿瘤临床科研专业委员会常委中国医药教育协会乳腺疾病专业委员会委员中国人体健康科技促进会乳腺疾病专业委员会委员中国抗癌协会肿瘤异质性与个体化治疗专业委员会委员中国研究型医院学会甲状腺疾病专业委员会委员陕西省日间医疗学会乳腺分会主任委员陕西省医学传播学会甲状腺疾病专委会副主任委员陕西省抗癌协会癌症筛查与早诊早治专业委员会常委陕西省健康促进与教育协会肿瘤防治专业委员会常委陕西省医师协会小儿外科医师分会常委陕西省抗癌协会乳腺癌专业委员会委员西安市癌症康复协会乳腺癌专业委员会常委丁嘉珺空军军医大学西京医院甲乳血管外科博士、住院医师以第一作者发表SCI论文2篇，参与发表SCI论文5篇参与国家级及省部级课题多项陕西省日间医疗学会乳腺分会委员专业特长：专注于乳腺疾病、甲状腺疾病的规范化治疗（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

AACR会议临床结果

2025-06-03

·BioPharmaDive

J&J data support earlier use of combo pill in prostate cancer

CHICAGO A Johnson & Johnson drug currently used for advanced prostate cancer can help keep the disease from progressing in men who are at earlier stages and have certain genetic mutations, according to newly unveiled data from a Phase 3 clinical trial.Results from this trial, named Amplitude, were released Tuesday at the American Society of Clinical Oncologys meeting in Chicago. They could potentially expand the number of people able to receive J&Js Akeega, a pill that combines the active ingredients from the medicines Zejula and Zytiga.Akeega, along with hormone therapy, kept men with so-called BRCA mutations from getting sicker for longer than Zytiga and hormone therapy, reducing the relative risk of disease progression by nearly half. The combination also reduced by 56% the risk that BRCA-positive participants in the study experienced symptoms of disease progression.Akeega is already approved for men whose disease stops responding to hormone therapy if they have BRCA mutations, which often signal a more aggressive cancer. This stage of disease, classified as castration resistant, is considered to be advanced.Akeegas constituent drug components target the proteins PARP and CYP17, respectively. Drugs aimed at CYP17 have been used in prostate cancer for more than a decade, while PARP inhibitors are more recent arrivals. However, in prostate cancer, PARP blockers are largely used in the castration-resistant setting, where testosterone suppression no longer keeps the disease in check.Some physicians and drugmakers have explored moving treatment to early-stage disease as a way of helping patients live longer. Amplitude was set up to test that hypothesis.The challenge is that when we use PARP inhibitors as monotherapy at the end of the treatment sequence, resistance rapidly develops, and the median time to radiographic progression-free survival is shorter than 12 months, said Gerhardt Attard, a professor of medical oncology at University College London and lead author of the study, in a press conference presenting the data. This group of patients have poor outcomes, significantly worse outcomes than other patients.Bradley McGregor, a genitourinary specialist with Dana-Farber Cancer Institute, said the study results will help clear up debate over where PARP inhibitors fit into treatment of people with hormone-sensitive disease. This data is quite compelling for the BRCA 1/2 patients where that magnitude of benefit is higher, he said.Amplitude enrolled men with a broader set of mutations to homologous recombination repair, or HRR, genes, of which BRCA is one. The benefit in the overall population was smaller, with Akeega reducing the risk of radiographic progression by 37% and symptomatic progression by half.Akeega is currently approved only for the narrow BRCA-mutated population. Of the PARP inhibitors on the market, only AstraZenecas Lynparza has won clearance for the broader HRR population, but its use is reserved for castration-resistant disease.Mark Wildgust, J&Js global medical affairs vice president for oncology, said the HRR results from Amplitude should stimulate some discussion with the Food and Drug Administration. The company must keep working with regulators to see if there is room or comfort to expand to that broader population, he said.Trial investigators also analyzed results by specific HRR mutations beyond BRCA. With some, like one called PALB2, patients didnt see any benefit, Wildgust said. I think with smaller patient groups, it's a bit more difficult, he added.Physicians will need to be able to identify the patients most likely to benefit, should Akeega gain an expanded approval in earlier-stage prostate cancer. You dont know if you dont test, McGregor said.Akeega first won approval in 2023. Johson & Johnson didnt report annual sales for the drug in 2024.GSK has some rights to Zejula, Akeegas PARP-inhibiting ingredient, by way of its 2019 acquisition of the drug's developer, Tesaro Bio. J&J had previously licensed rights to niraparib in prostate cancer specifically, allowing it to market Akeega. '

临床结果上市批准并购临床3期ASCO会议

2025-05-23

·PMLiVE

Researchers uncover promising treatment approach for inherited breast cancer

A study led by Addenbrooke’s Hospital in Cambridge has found that a new treatment approach can significantly improve survival rates among patients with aggressive, inherited breast cancers. The research, published in Nature Communications , showed that 100% of patients who were treated with chemotherapy followed by the targeted cancer drug olaparib before surgery survived the critical three-year post-surgery period, when there is the greatest risk of relapse or death. Approximately 55,000 people are diagnosed with breast cancer every year in the UK, and cases linked to faulty copies of the BRCA1 and BRCA2 genes are challenging to treat. Patients typically receive chemotherapy and immunotherapy to shrink their tumour, before undergoing surgery to remove it. Olaparib tablets, marketed under the brand name Lynparza, are already available on the NHS for certain breast cancer indications and work by inhibiting the PARP enzyme, which helps cells repair damaged DNA. By blocking this enzyme, PARP inhibitors prevent the DNA of cancer cells being repaired, preventing them from growing and spreading. The Partner trial enrolled patients with early-stage breast cancer and inherited BRCA1 and BRCA2 mutations from 23 NHS sites across the UK and showed that leaving a 48-hour gap between chemotherapy and olaparib improved patient outcomes. The team noted that this could be due to patients’ bone marrow having time to recover from chemotherapy, while leaving the tumour cells susceptible to olaparib. Among the 39 patients treated with chemotherapy followed by olaparib, only one relapsed three years post-surgery and 100% survived. This is compared to nine of the 45 patients in the chemotherapy-only cohort relapsing, and an 88% survival rate at the same time point. Addenbrooke’s consultant and trial lead, Jean Abraham, said: “It is rare to have a 100% survival rate in a study like this and for these aggressive types of cancer. We’re incredibly excited about the potential of this new approach, as it’s crucial that we find a way to treat and hopefully cure patients who are diagnosed with BRCA1 and BRCA2 related cancers.” The team will now aim to replicate the results in a larger study and confirm that the new approach offers a less toxic treatment for patients compared to the current standard of care. The research will also aim to demonstrate that the approach is more cost effective, as olaparib-treated patients are currently given the drug post-surgery for 12 months, while patients in the Partner trial took the tablets pre-surgery for 12 weeks. The trial was funded by AstraZeneca and Cancer Research UK, sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, and supported by the NIHR Cambridge Biomedical Research Centre, the Cancer Research UK Cambridge Centre and Addenbrooke’s Charitable Trust.

临床结果临床研究免疫疗法上市批准

100 项与 3-Aminobenzamide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05549

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏病	临床2期	美国	Inotek Pharmaceuticals Corp.	2005-10-01
心脏病	临床2期	澳大利亚	Inotek Pharmaceuticals Corp.	2005-10-01
心脏病	临床2期	印度	Inotek Pharmaceuticals Corp.	2005-10-01
心脏病	临床2期	以色列	Inotek Pharmaceuticals Corp.	2005-10-01
术后并发症	临床2期	美国	Inotek Pharmaceuticals Corp.	2005-10-01
术后并发症	临床2期	澳大利亚	Inotek Pharmaceuticals Corp.	2005-10-01
术后并发症	临床2期	印度	Inotek Pharmaceuticals Corp.	2005-10-01
术后并发症	临床2期	以色列	Inotek Pharmaceuticals Corp.	2005-10-01
急性心肌梗塞	临床2期	美国	Inotek Pharmaceuticals Corp.	2004-01-01
急性心肌梗塞	临床2期	以色列	Inotek Pharmaceuticals Corp.	2004-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00271765 (TIMI 37, Pubmed \| J Thromb Thrombolysis)	临床2期	ST段抬高心肌梗死	40	INO-1001	築願範構製製鹹鑰範鑰(築觸製蓋築鹹鑰鬱艱範) = Serial C-reactive protein levels showed a trend toward blunting of inflammation with INO-1001 選鏇鏇糧鹹繭鑰壓艱蓋 (衊憲顧憲鏇鹹鬱蓋簾蓋 ) 更多	-	2009-05-01